Measuring COVID-19 Humoral Immune Response with Ultrasensitive, Cell-Free, PCR-Based Neutralizing Antibody Assays
Title: Measuring COVID-19 Humoral Immune Response with Ultrasensitive, Cell-Free, PCR-Based Neutralizing Antibody Assays
Date: October 5, 2022
Time: 1 p.m. ET
Presenter: Feng Xuan
Build a Complete Picture of Immune Response
As we look to manage the next phase of the pandemic, it is important to understand the body’s immune response to SARS-CoV-2 vaccines. Most antibody testing detects all antibodies in a sample, although only neutralizing antibodies (NAbs) inhibit the virus from attaching to cells. Building a complete picture of immune response, including the role of NAbs, is critical as we face the continued emergence of new variants.
However, cell-based assays, the current gold standard for SARS-CoV-2 NAb testing, require additional safety measures for managing live viruses. These involve long, complicated workflows with poor lab-to-lab consistency. While some Elisa-based solutions are available, they lack sensitivity and don’t produce a quantitative measurement.
In this webinar we will learn about a new approach to this problem using a new proprietary method that leverages qPCR to produce quantified Nab titers.
This webinar will help you:
- Explain the importance of NAb testing and the need for standard testing methods
- Review current COVID-19 antibody testing options
- Describe a new technology being used for SARS-CoV-2 NAb testing
- Examine NAb data for vaccination and emerging variants
For research use only. Not for diagnostic procedures.
Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.
Feng Xuan, Chief Technical Officer and Co-Founder of Spear Bio
Before joining Spear Bio, Feng Xuan was a technology development fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University. There, he invented the Spear Bio core technology. Feng received a Bachelor of Science in chemistry and a master’s degree in philosophy of biomedical engineering from Hong Kong University of Science and Technology.